Comerica Bank
ARQT icon

Comerica Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Comerica Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.74K Sell
95
-40
-30% -$1.02K ﹤0.01% 3491
2025
Q3 		$2.54K Sell
135
-1,507
-92% -$23.8K ﹤0.01% 3498
2025
Q2 		$23K Buy
1,642
+1,141
+228% +$16K ﹤0.01% 3012
2025
Q1 		$7.83K Buy
501
+26
+5% +$366 ﹤0.01% 3230
2024
Q4 		$6.62K Hold
475
– – ﹤0.01% 3253
2024
Q3 		$4.42K Buy
475
+318
+203% +$3.14K ﹤0.01% 3364
2024
Q2 		$1.46K Sell
157
-182
-54% -$1.65K ﹤0.01% 3542
2024
Q1 		$3.36K Buy
339
+249
+277% +$1.86K ﹤0.01% 3424
2023
Q4 		$291 Hold
90
– – ﹤0.01% 3690
2023
Q3 		$478 Buy
+90
New +$765 ﹤0.01% 3717

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Comerica Bank's ARQT Position: Q4 2025 in Review

Comerica Bank reduced its Arcutis Biotherapeutics (ARQT) stake by 30% in Q4 2025, selling an estimated $1.02K and leaving 95 shares worth $2.74K. The position accounts for ﹤0.01% of the portfolio, ranked #3491.

Comerica Bank first reported a position in ARQT in Q3 2023 and has held it in 10 quarters since. The position peaked at $23K in Q2 2025. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Comerica Bank held 95 shares of Arcutis Biotherapeutics worth $2.74K as of Q4 2025.
  • Comerica Bank sold 40 Arcutis Biotherapeutics shares in Q4 2025, an estimated $1.02K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3491 holding.
  • Comerica Bank first reported a position in Arcutis Biotherapeutics in Q3 2023 and has held it in 10 quarters since.
  • Comerica Bank's Arcutis Biotherapeutics position peaked at $23K in Q2 2025.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.